Clinical Trial Update: Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Vosaroxin in adults with intermediate-2 or high-risk myelodysplastic syndrome after failure of hypomethylating therapy; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Vosaroxin (voreloxin) (vosaroxin)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-12-28